U.S. Food and Drug Administration approved Rasonque (daraxonrasib), developed by Revolution Medicines, for the treatment of metastatic pancreatic adenocarcinoma.
The medication is indicated for adults who have received at least one prior line of systemic therapy or who are not candidates for multiagent systemic treatment.
Rasonque is the first approved therapy in a new class of medicines designed to target multiple forms of RAS proteins—one of the key molecular drivers of pancreatic cancer. The approval was confirmed in official announcements from the U.S. Food and Drug Administration and Revolution Medicines.
Who May Be Eligible for Rasonque?
According to the FDA-approved indication, Rasonque may be prescribed to adults who:
- have metastatic pancreatic adenocarcinoma;
- have received at least one previous systemic therapy; or
- are not medically suitable candidates for multiagent systemic treatment.
The current approval applies in the United States. At the time of publication, daraxonrasib had not yet received regulatory approval in Israel or other countries.
The possibility of receiving the medication outside the United States, including through special access pathways, must be evaluated individually by a qualified oncologist and is subject to medical indications and applicable regulations.
How Does Daraxonrasib Work?
Daraxonrasib is an oral inhibitor of the RAS GTPase family. It blocks RAS proteins in their active state, thereby disrupting the molecular signals that encourage cancer cells to grow and divide.
Abnormal activation of the RAS signaling pathway plays a central role in pancreatic cancer. Oncogenic RAS mutations—most commonly involving the KRAS gene—are found in more than 90% of pancreatic ductal adenocarcinomas.
For many years, KRAS and other members of the RAS family were considered extremely difficult to target directly with medication. The development of therapies capable of inhibiting this pathway has therefore become one of the most important advances in modern molecular oncology.
Unlike treatments directed at a single mutation, Rasonque targets multiple mutant and non-mutant forms of RAS. As a result, the FDA-approved indication does not require patients to have a particular RAS mutation or undergo testing with a specific companion diagnostic before treatment.
Nevertheless, comprehensive molecular testing may still provide valuable information when developing an individualized treatment strategy.
Results of the RASolute 302 Trial
The FDA approval was based on the results of RASolute 302, an international randomized Phase III clinical trial involving 500 patients with previously treated metastatic pancreatic adenocarcinoma.
Participants were divided into two groups:
- 248 patients received daraxonrasib;
- 252 patients received the physician’s choice of standard chemotherapy.
Rasonque was administered as a standalone treatment rather than in combination with chemotherapy.
Key Results
Median overall survival was:
- 13.2 months with daraxonrasib;
- 6.7 months with standard chemotherapy.
Daraxonrasib reduced the risk of death by 60% compared with standard chemotherapy.
Median progression-free survival was:
- 7.2 months with daraxonrasib;
- 3.6 months with chemotherapy.
An objective tumor response was recorded in:
- 30% of patients receiving daraxonrasib;
- 11% of patients receiving chemotherapy.
Patients treated with daraxonrasib also maintained their quality of life for longer and experienced a later worsening of pain compared with patients who received chemotherapy.
These figures represent median trial results. The outcome for an individual patient may vary considerably depending on their general health, previous treatments, the biological characteristics of the tumor, the extent of the disease and the tumor’s response to therapy.
How Is Rasonque Taken?
Rasonque is supplied in tablet form and is taken orally once a day. The FDA-approved dose is 300 mg daily.
The treatment schedule and any decision to interrupt treatment, reduce the dose or discontinue the medication must be determined by the treating oncologist.
Daraxonrasib is a prescription cancer therapy and must not be taken without specialist supervision.
Possible Side Effects
The most commonly reported adverse reactions include:
- skin rash and other dermatological reactions;
- diarrhea;
- stomatitis, inflammation or ulceration of the oral mucosa;
- nausea and vomiting;
- fatigue;
- abdominal pain;
- edema;
- decreased appetite;
- bleeding.
The prescribing information also includes warnings concerning severe dermatological and soft-tissue toxicity, gastrointestinal perforation and interstitial lung disease or pneumonitis.
Patients require regular oncological monitoring throughout treatment. Depending on the type and severity of adverse reactions, the physician may prescribe supportive treatment, temporarily interrupt therapy, reduce the dose or permanently discontinue the medication.
Why Is the Approval of Rasonque Important?
Pancreatic cancer remains one of the most aggressive oncological diseases. Early-stage tumors often cause no distinctive symptoms, and many patients are diagnosed only after the cancer has spread to other organs.
Until now, treatment options following disease progression after first-line therapy have been limited. Daraxonrasib is the first RAS inhibitor to demonstrate a substantial survival advantage over standard chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma.
The new medication is not a universal treatment and cannot guarantee the same outcome for every patient. However, its approval significantly expands the available therapeutic options and confirms the potential of directly targeting the RAS signaling pathway.
Daraxonrasib is also being investigated in other RAS-related tumors, including certain forms of non-small cell lung cancer and colorectal cancer. These applications remain investigational and are not currently included in the FDA-approved indication for Rasonque.
Pancreatic Cancer Treatment with Leading Israeli Specialists
Selecting the most appropriate treatment for metastatic pancreatic cancer requires a highly individualized approach. The decision may depend on:
- previously administered treatments;
- the patient’s general health and functional status;
- the extent and location of metastases;
- biopsy and pathology findings;
- the molecular and genetic characteristics of the tumor;
- the expected benefits and risks of each treatment option.
Through Sapir Medical Clinic, international patients can access consultations and treatment planning by leading Israeli oncologists specializing in pancreatic and gastrointestinal cancers.
Depending on the individual medical situation, Sapir Medical Clinic can arrange:
- consultation with a leading Israeli gastrointestinal oncologist;
- a second medical opinion from an Israeli cancer specialist;
- review of biopsy specimens and pathology reports;
- comprehensive molecular and genetic tumor profiling;
- development of an individualized cancer treatment program;
- evaluation of modern targeted therapies;
- assessment of eligibility for relevant clinical trials;
- evaluation of possible access to medications not yet registered in Israel;
- coordination of diagnostics and treatment at leading Israeli medical centers.
The specialists assess each case on the basis of the patient’s medical history, previous treatments, imaging results, pathology findings and molecular tumor profile. This allows them to determine which therapeutic options may be medically appropriate and whether additional testing is required.
Sapir Medical Clinic assists patients throughout the process—from obtaining an expert medical opinion and selecting the appropriate specialist to organizing advanced diagnostics and treatment in Israel.
For a preliminary case assessment, patients may submit:
- hospital discharge summaries and medical reports;
- biopsy and pathology results;
- CT, MRI or PET-CT images and reports;
- information about previous surgery, chemotherapy or radiotherapy;
- molecular and genetic testing results;
- a current list of medications.
Contact Sapir Medical Clinic
Sapir Medical Clinic provides access to leading Israeli oncologists, advanced molecular diagnostics and individualized treatment planning for pancreatic cancer and other oncological conditions.
To request a consultation or preliminary assessment, contact:
Important: This article is intended for informational purposes only. It does not constitute advertising for a medicinal product and cannot replace an individual medical consultation. The indication for Rasonque, its availability and the possibility of receiving treatment must be determined by a qualified oncologist.